BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chu Q, Xu H, Gao M, Guan X, Liu H, Deng S, Huo X, Liu K, Tian Y, Ma X. Liver-targeting Resibufogenin-loaded poly(lactic-co-glycolic acid)-D-α-tocopheryl polyethylene glycol 1000 succinate nanoparticles for liver cancer therapy. Int J Nanomedicine 2016;11:449-63. [PMID: 26869788 DOI: 10.2147/IJN.S93541] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
Number Citing Articles
1 Han Q, Ma Y, Wang H, Dai Y, Chen C, Liu Y, Jing L, Sun X. Resibufogenin suppresses colorectal cancer growth and metastasis through RIP3-mediated necroptosis. J Transl Med. 2018;16:201. [PMID: 30029665 DOI: 10.1186/s12967-018-1580-x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 7.3] [Reference Citation Analysis]
2 Yang C, Wu T, Qi Y, Zhang Z. Recent Advances in the Application of Vitamin E TPGS for Drug Delivery. Theranostics 2018;8:464-85. [PMID: 29290821 DOI: 10.7150/thno.22711] [Cited by in Crossref: 188] [Cited by in F6Publishing: 167] [Article Influence: 47.0] [Reference Citation Analysis]
3 Li H, Tian J, Wu A, Wang J, Ge C, Sun Z. Self-assembled silk fibroin nanoparticles loaded with binary drugs in the treatment of breast carcinoma. Int J Nanomedicine 2016;11:4373-80. [PMID: 27621628 DOI: 10.2147/IJN.S108633] [Cited by in Crossref: 27] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
4 Lu Z, Xu A, Yuan X, Chen K, Wang L, Guo T. Anticancer effect of resibufogenin on gastric carcinoma cells through the phosphoinositide 3-kinase/protein kinase B/glycogen synthase kinase 3β signaling pathway. Oncol Lett 2018;16:3297-302. [PMID: 30127928 DOI: 10.3892/ol.2018.8979] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Yang T, Jiang YX, Wu Y, Lu D, Huang R, Wang LL, Wang SQ, Guan YY, Zhang H, Luan X. Resibufogenin Suppresses Triple-Negative Breast Cancer Angiogenesis by Blocking VEGFR2-Mediated Signaling Pathway. Front Pharmacol 2021;12:682735. [PMID: 33995111 DOI: 10.3389/fphar.2021.682735] [Reference Citation Analysis]
6 Dong H, Tian L, Gao M, Xu H, Zhang C, Lv L, Zhang J, Wang C, Tian Y, Ma X. Promising galactose-decorated biodegradable poloxamer 188-PLGA diblock copolymer nanoparticles of resibufogenin for enhancing liver cancer therapy. Drug Deliv 2017;24:1302-16. [PMID: 28895767 DOI: 10.1080/10717544.2017.1373165] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]